Methods: Preterm fetuses (0.6 gestation) underwent single umbilical artery ligation (SUAL) to induce FGR. Ewes were randomly allocated to receive saline or sildenafil (SC). Ewes and fetuses were instrumented to record in vivo physiology. At 0.83 gestation lambs underwent post-mortem for in vitro analysis of cerebral and femoral artery functional.
Methods: Preterm fetuses (0.6 gestation) underwent single umbilical artery ligation (SUAL) to induce FGR. Ewes were randomly allocated to receive saline or sildenafil (SC). Ewes and fetuses were instrumented to record in vivo physiology. At 0.83 gestation lambs underwent post-mortem for in vitro analysis of cerebral and femoral artery functional.
Results: SUAL caused 25% reduction in weight compared to appropriately grown (AG) (P = 0.03), growth deficits were exacerbated following SC treatment (FGR SC , 50% reduction, P < 0.01). Despite a similar degree of hypoxia in both FGR and FGR SC fetuses compared to AG (P < 0.05) only FGR fetuses increased carotid to femoral blood flow indicative of brain sparing (P < 0.01). In-vitro assessment of vascular function revealed preservation of function in the cerebral circulation in FGR and AG fetuses, as compared to FGR SC fetuses where significant cerebral vascular dysfunction was observed.
Conclusions: Maternal SC treatment resulted in fetal hypoxia and an exacerbation of growth deficits. SC impaired the fetal ability to mount cardiovascular adaptations to hypoxia and also impaired vascular function. Our findings inform the mechanisms by which SC may impair development in severely growth restricted fetuses. Background: Breath synchronized aerosol surfactant may provide an alternative to bolus surfactant administration for preterm infants.
Objectives: Evaluate safety, tolerability of Aerofact TM inhaled surfactant via nCPAP to preterm infants, comparing need for rescue to matched historical controls (HC). Design/Methods: Open label multi-center study. Infants 26 -30 6/7w GA, < 2 h of age, requiring nCPAP 6-8 cm H 2 O and FiO2< 0.30, were consented and enrolled. Part I: a single dose of 216 mg/kg nebulized surfactant. Part II: an initial dose of 216 mg/kg nebulized surfactant with up to 3 additional doses within 72 h of age. Infants followed until discharge. Treatment failure (TF): respiratory severity score (RSS; FiO2 x CPAP) ≥ 2.4, PaCO2 > 65 or pH < 7.20, nCPAP > 8 cmH2O or 3 severe apneas assessed through 7 days. 3 HC matched for each enrolled infant.
Results: 68 infants screened from two clinical sites. 10 infants enrolled into Part I and 20 into Part II (per protocol population). Average (range) GA was 28.1 (26/2-30/4) weeks and birth weight 1169 (649-1664) g. No safety issues identified. There were 2 infant deaths unrelated to study treatment. Part I: TF (4/10 (40%) was lower in enrolled infants than (14/30 (47%) HC (P<0.06) Part II: TF in 6/20 (33%) in enrolled infants was lower than 35/60 (56%) HC (P<0.11).
Conclusion: Aerofact TM inhaled surfactant with nCPAP was safe and well tolerated with a trend towards lower TF compared to HC. A larger randomised controlled trial will be undertaken to determine efficacy. Background: Predicting which extremely preterm infants (EPI, <28 weeks') will be successfully extubated to noninvasive ventilation is difficult. We aimed to compare the characteristics and outcomes of EPI who had extubation success and failure.
EXTUBATION CHARACTERISTICS OF EXTREMELY PRETERM INFANTS
Methods: Single centre retrospective audit of the first extubation of EPI conducted between 2016-2017. Extubation failure was defined as reintubation within 7 days.
Results: Forty-two of 87(49%) EPI required reintubation. There were important differences in the characteristics of infants in both groups. Infants requiring reintubation had poorer outcomes than those who did not (table) . In a multivariable regression model GA remained the only significant predictor of extubation success (area under a receiver operating characteristic curve = 0.73). Conclusions: Lower GA and birthweight and greater ventilator support are associated with an increased risk of extubation failure. Failure is associated with longer durations of supplemental oxygen and hospitalisation and an increased risk of BPD.
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